{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"description":"This outcome measure was to assess the safety and tolerability of bortezomib, dexamethasone and rituximab in patients with untreated Waldenstroms macroglobulinemia.","groups":[{"description":"A cycle of therapy consisted of bortezomib 1.3 mg/m(2) intravenously; dexamethasone 40 mg on days 1, 4, 8, and 11; and rituximab 375 mg/m(2) on day 11. Patients received four consecutive cycles for induction therapy and then four more cycles, each given 3 months apart, for maintenance therapy.","id":"OG000","title":"Bortezomib, Dexamethasone, Rituximab"}],"paramType":"NUMBER","populationDescription":"All enrolled patients","reportingStatus":"POSTED","timeFrame":"33.2 months","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"participants"}